Abbvie Limited
Lobbying activity
The following activities occurred for this specific Subject Matter Area.
Email (2-5)
Emails requesting meetings
Meeting (6-10)
Meetings to deliver briefing on Ireland's low rate of availability of new medicines compared to other European countries . Ireland ranks 18 out of 26 European Countries in availability of new medicines. To call on the Government to address Ireland being slow and late in reimbursing new medicines with a Medicines Access policy that will put Ireland back in line with the rest of Europe. To ask that this policy consider new pathways for orphan medicines and medicines getting early regulatory approval at phase II where a full HTA is not feasable
Submission (1)
Post meeting with An Taoiseach submitted a copy of the HSE proposal for reimbursement for a new innovative medicine for Chronic Lymphocyctic Leukemia (CLL)
Letter (2-5)
letters to Taoiseach Office and Leaders of the Opposition to meet with senior leaders from AbbVie who were attending the BioPharma Ambition conference in Dublin.
Designated public officials lobbied
The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.